Endothelin receptor antagonists in diabetic and non-diabetic chronic kidney disease

Area of Science:

• Nephrology
• Pharmacology

Background:

• Chronic kidney disease (CKD) affects over 800 million people globally, representing a significant cause of morbidity and mortality.
• Current therapeutic options for CKD often lack targeted approaches for underlying pathophysiologic processes.
• The endothelin system plays a role in CKD pathophysiology, suggesting potential therapeutic targets.

Purpose of the Study:

• To review recent findings on the safety and efficacy of endothelin receptor antagonists (ERAs) in patients with CKD.
• To examine the role of ERAs in both diabetic and non-diabetic CKD populations.
• To discuss future research directions and emerging treatments in CKD therapy.

Main Methods:

• Systematic review of recent clinical trials and relevant literature.
• Analysis of safety and efficacy data for endothelin receptor antagonists.
• Synthesis of evidence regarding the impact of ERAs on diabetic and non-diabetic CKD.

Main Results:

• Endothelin receptor antagonists demonstrate increasing evidence of efficacy in CKD patients.
• Data on the safety and effectiveness of ERAs in diabetic and non-diabetic CKD are being actively investigated.
• Recent trials indicate a shifting landscape with promising new therapeutic avenues for CKD.

Conclusions:

• Endothelin receptor antagonists represent a promising therapeutic class for managing chronic kidney disease.
• Further research is warranted to fully elucidate the long-term safety and efficacy profiles of ERAs across diverse CKD populations.
• The findings support the exploration of ERAs as a targeted therapy for CKD, addressing key pathophysiologic mechanisms.